167 related articles for article (PubMed ID: 23940673)
1. Neuronal apoptosis and motor deficits in mice with genetic inhibition of GSK-3 are Fas-dependent.
Gómez-Sintes R; Lucas JJ
PLoS One; 2013; 8(8):e70952. PubMed ID: 23940673
[TBL] [Abstract][Full Text] [Related]
2. NFAT/Fas signaling mediates the neuronal apoptosis and motor side effects of GSK-3 inhibition in a mouse model of lithium therapy.
Gómez-Sintes R; Lucas JJ
J Clin Invest; 2010 Jul; 120(7):2432-45. PubMed ID: 20530871
[TBL] [Abstract][Full Text] [Related]
3. Neuronal apoptosis and reversible motor deficit in dominant-negative GSK-3 conditional transgenic mice.
Gómez-Sintes R; Hernández F; Bortolozzi A; Artigas F; Avila J; Zaratin P; Gotteland JP; Lucas JJ
EMBO J; 2007 Jun; 26(11):2743-54. PubMed ID: 17510631
[TBL] [Abstract][Full Text] [Related]
4. The neuroprotective effect of the GSK-3β inhibitor and influence on the extrinsic apoptosis in the ALS transgenic mice.
Ahn SW; Kim JE; Park KS; Choi WJ; Hong YH; Kim SM; Kim SH; Lee KW; Sung JJ
J Neurol Sci; 2012 Sep; 320(1-2):1-5. PubMed ID: 22698482
[TBL] [Abstract][Full Text] [Related]
5. Reduced striatal dopamine DA D2 receptor function in dominant-negative GSK-3 transgenic mice.
Gomez-Sintes R; Bortolozzi A; Artigas F; Lucas JJ
Eur Neuropsychopharmacol; 2014 Sep; 24(9):1524-33. PubMed ID: 25088904
[TBL] [Abstract][Full Text] [Related]
6. Motor learning deficits and striatal GSK-3 hyperactivity in Akt3 knockout mice.
Ouimet B; Pépin É; Bergeron Y; Chagniel L; Beaulieu JM; Massicotte G; Cyr M
Behav Neurosci; 2019 Feb; 133(1):135-143. PubMed ID: 30688489
[TBL] [Abstract][Full Text] [Related]
7. Decreased glycogen synthase kinase-3 levels and activity contribute to Huntington's disease.
Fernández-Nogales M; Hernández F; Miguez A; Alberch J; Ginés S; Pérez-Navarro E; Lucas JJ
Hum Mol Genet; 2015 Sep; 24(17):5040-52. PubMed ID: 26082469
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of glycogen synthase kinase-3beta protects dopaminergic neurons from MPTP toxicity.
Wang W; Yang Y; Ying C; Li W; Ruan H; Zhu X; You Y; Han Y; Chen R; Wang Y; Li M
Neuropharmacology; 2007 Jun; 52(8):1678-84. PubMed ID: 17517424
[TBL] [Abstract][Full Text] [Related]
9. Full reversal of Alzheimer's disease-like phenotype in a mouse model with conditional overexpression of glycogen synthase kinase-3.
Engel T; Hernández F; Avila J; Lucas JJ
J Neurosci; 2006 May; 26(19):5083-90. PubMed ID: 16687499
[TBL] [Abstract][Full Text] [Related]
10. Combined lithium and valproate treatment delays disease onset, reduces neurological deficits and prolongs survival in an amyotrophic lateral sclerosis mouse model.
Feng HL; Leng Y; Ma CH; Zhang J; Ren M; Chuang DM
Neuroscience; 2008 Aug; 155(3):567-72. PubMed ID: 18640245
[TBL] [Abstract][Full Text] [Related]
11. Glycogen synthase kinase-3beta heterozygote knockout mice as a model of findings in postmortem schizophrenia brain or as a model of behaviors mimicking lithium action: negative results.
Bersudsky Y; Shaldubina A; Kozlovsky N; Woodgett JR; Agam G; Belmaker RH
Behav Pharmacol; 2008 May; 19(3):217-24. PubMed ID: 18469539
[TBL] [Abstract][Full Text] [Related]
12. Synergistic neuroprotective effects of lithium and valproic acid or other histone deacetylase inhibitors in neurons: roles of glycogen synthase kinase-3 inhibition.
Leng Y; Liang MH; Ren M; Marinova Z; Leeds P; Chuang DM
J Neurosci; 2008 Mar; 28(10):2576-88. PubMed ID: 18322101
[TBL] [Abstract][Full Text] [Related]
13. Chronic lithium administration to FTDP-17 tau and GSK-3beta overexpressing mice prevents tau hyperphosphorylation and neurofibrillary tangle formation, but pre-formed neurofibrillary tangles do not revert.
Engel T; Goñi-Oliver P; Lucas JJ; Avila J; Hernández F
J Neurochem; 2006 Dec; 99(6):1445-55. PubMed ID: 17059563
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of glycogen synthase kinase 3 beta attenuates neurocognitive dysfunction resulting from cranial irradiation.
Thotala DK; Hallahan DE; Yazlovitskaya EM
Cancer Res; 2008 Jul; 68(14):5859-68. PubMed ID: 18632640
[TBL] [Abstract][Full Text] [Related]
15. Lithium-mediated phosphorylation of glycogen synthase kinase-3beta involves PI3 kinase-dependent activation of protein kinase C-alpha.
Kirshenboim N; Plotkin B; Shlomo SB; Kaidanovich-Beilin O; Eldar-Finkelman H
J Mol Neurosci; 2004; 24(2):237-45. PubMed ID: 15456937
[TBL] [Abstract][Full Text] [Related]
16. AKT kinase activity is required for lithium to modulate mood-related behaviors in mice.
Pan JQ; Lewis MC; Ketterman JK; Clore EL; Riley M; Richards KR; Berry-Scott E; Liu X; Wagner FF; Holson EB; Neve RL; Biechele TL; Moon RT; Scolnick EM; Petryshen TL; Haggarty SJ
Neuropsychopharmacology; 2011 Jun; 36(7):1397-411. PubMed ID: 21389981
[TBL] [Abstract][Full Text] [Related]
17. GSK-3beta inhibition by lithium confers resistance to chemotherapy-induced apoptosis through the repression of CD95 (Fas/APO-1) expression.
Beurel E; Kornprobst M; Blivet-Van Eggelpoël MJ; Ruiz-Ruiz C; Cadoret A; Capeau J; Desbois-Mouthon C
Exp Cell Res; 2004 Nov; 300(2):354-64. PubMed ID: 15475000
[TBL] [Abstract][Full Text] [Related]
18. Glycogen synthase kinase-3 is essential for β-arrestin-2 complex formation and lithium-sensitive behaviors in mice.
O'Brien WT; Huang J; Buccafusca R; Garskof J; Valvezan AJ; Berry GT; Klein PS
J Clin Invest; 2011 Sep; 121(9):3756-62. PubMed ID: 21821916
[TBL] [Abstract][Full Text] [Related]
19. Glycogen synthase kinase-3beta induces neuronal cell death via direct phosphorylation of mixed lineage kinase 3.
Mishra R; Barthwal MK; Sondarva G; Rana B; Wong L; Chatterjee M; Woodgett JR; Rana A
J Biol Chem; 2007 Oct; 282(42):30393-405. PubMed ID: 17711861
[TBL] [Abstract][Full Text] [Related]
20. Involvment of cytosolic and mitochondrial GSK-3beta in mitochondrial dysfunction and neuronal cell death of MPTP/MPP-treated neurons.
Petit-Paitel A; Brau F; Cazareth J; Chabry J
PLoS One; 2009; 4(5):e5491. PubMed ID: 19430525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
